A resident company of the Sid Martin Biotechnology Institute at the University of Florida, Medosome Biotec identifies drugs to treat pediatric orphan diseases.

ALACHUA, FLORIDA, USA, February 13, 2017 /EINPresswire.com/ -- Medosome Biotec, LLC (MBT), a biotechnology company focused on genetically-based personalized medicine, has been awarded two National Institutes of Health (NIH) Small Business Technology Transfer Research (STTR) Phase I grants to support the company’s development of orphan drug products and personalized medicine. One grant is for the treatment of periventricular white matter injury, a serious condition affecting brain development in premature infants. The second grant is for the treatment of MEGF10 myopathy, a disease related to muscular dystrophy. Both products involved the in-house development of novel screens for selecting the drug compounds. Complementary genetic and biomarker tests are being developed to assist in the diagnosis and/or personalized dosing of the orphan drugs.

Orphan drugs are intended for the effective treatment, diagnosis or prevention of rare diseases/disorders that affect fewer than 200,000 people in the U.S. and are given a special status and regulatory pathway by the FDA.

“We are excited to move forward with this funding in developing our technology platform,” stated Richard Wagner, CEO of Medosome Biotec. “The STTR grants support our efforts to advance these orphan drugs that can have great patient benefit.”

Mark S. Long, Director of the Sid Martin Biotechnology Institute, said, “The importance of Medosome Biotec’s research is reflected in the company being awarded the two grants. The National Institutes of Health recognizes Medosome for their significant progress in developing orphan drug products for the treatment of childhood diseases.”

Medosome Biotec is focused on identifying drugs to treat pediatric orphan diseases as well as the development of complementary genetic tests for personalized dosing of drugs for the treatment of orphan diseases. The company operates a CLIA certified and CAP accredited Florida licensed clinical genetic testing laboratory. Many of MBT’s projects, such as the one proposed in this particular application, are executed in close collaboration with researchers in the Departments of Medicine and Pediatrics at the University of Florida.

About Medosome Biotec, LLC

Located at the Sid Martin Biotechnology Institute in Progress Park, Florida, Medosome Biotec, LLC (MBT) is developing and commercializing technologies that enrich the lives of children by providing genetic-based solutions to childhood diseases, disabilities and deficiencies. MBT works in collaboration with the Department of Pediatrics and Department of Medicine in the College of Medicine at the University of Florida to expedite the commercialization of the technologies created in these departments. For more information, please visit www.mdbiotec.com.

About the Sid Martin Biotechnology Institute at the University of Florida

The Sid Martin Biotechnology Institute is the leading biotechnology incubator headquartered at the University of Florida in Alachua, Florida at Progress Park. The Institute has been honored with national and international awards for incubator excellence and achievements in technology commercialization, funding access, job creation and technology-based economic development. It is dedicated to mentoring and accelerating the growth of innovative early-stage bioscience and biotechnology companies, and supporting the economic growth of the North Central Florida region. For more information, visit www.sidmartbio.org.

Merrie Shaw, Assistant Director
UF/Sid Martin Biotechnology Institute
386-462-0880
email us here

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.